Selisistat

DB13978InvestigationalSmall molecule

Selective inhibitor of SIRT1 that does not inhibit histone deacetylase (HDAC) or other sirtuin deacetylase family members (IC50 values are 98, 19600, 48700, > 100000 and > 100000 nM for... Enhances p53 acetylation in response to DNA damaging agents.

Mechanism: Pharmacologically active on NAD-dependent protein deacetylase sirtuin-1
Curator reviewed
Formula / weight: C₁₃H₁₃ClN₂O · 248.71 g/mol (avg)
Code names: EX-527

Resolves to

Compound

UNIIL19ECD5014CAS49843-98-3ChEMBLCHEMBL420311ChEBI90369

Structure

InChIKeyFUZYTVDVLBBXDL-UHFFFAOYSA-NSMILESNC(=O)C1CCCC2=C1NC1=C2C=C(Cl)C=C1

Targets

Q96EB6SIRT1

What you can answer from here — as of April 23, 2025

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

1Clinical trialPhase, status and sponsor resolved per trial

4+ReferencesStructured and connected to the statements they support

Which drugs share a target with Selisistat, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account